PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Alaleh Nouri Sells 10,000 Shares

PROCEPT BioRobotics Co. (NASDAQ:PRCTGet Free Report) EVP Alaleh Nouri sold 10,000 shares of the stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $62.18, for a total transaction of $621,800.00. Following the completion of the transaction, the executive vice president now directly owns 52,472 shares of the company’s stock, valued at approximately $3,262,708.96. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Alaleh Nouri also recently made the following trade(s):

  • On Friday, May 3rd, Alaleh Nouri sold 30,432 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $62.97, for a total transaction of $1,916,303.04.

PROCEPT BioRobotics Trading Down 0.1 %

NASDAQ PRCT traded down $0.04 on Tuesday, hitting $62.00. The company’s stock had a trading volume of 558,318 shares, compared to its average volume of 549,031. The company has a quick ratio of 7.44, a current ratio of 8.52 and a debt-to-equity ratio of 0.19. PROCEPT BioRobotics Co. has a 1-year low of $24.83 and a 1-year high of $77.00. The company’s 50-day moving average is $61.06 and its 200 day moving average is $51.30. The firm has a market cap of $3.19 billion, a PE ratio of -29.04 and a beta of 1.04.

PROCEPT BioRobotics (NASDAQ:PRCTGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.04. PROCEPT BioRobotics had a negative net margin of 66.12% and a negative return on equity of 41.35%. The company had revenue of $44.50 million during the quarter, compared to analysts’ expectations of $41.58 million. During the same period in the prior year, the company posted ($0.63) earnings per share. PROCEPT BioRobotics’s revenue for the quarter was up 82.4% compared to the same quarter last year. As a group, analysts predict that PROCEPT BioRobotics Co. will post -1.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PROCEPT BioRobotics

A number of large investors have recently bought and sold shares of PRCT. Fairman Group LLC acquired a new stake in PROCEPT BioRobotics in the fourth quarter worth $84,000. Blue Trust Inc. grew its holdings in PROCEPT BioRobotics by 30.9% in the fourth quarter. Blue Trust Inc. now owns 2,629 shares of the company’s stock worth $110,000 after purchasing an additional 620 shares during the period. Glass Jacobson Investment Advisors llc bought a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at $138,000. Amalgamated Bank lifted its stake in shares of PROCEPT BioRobotics by 8.8% in the third quarter. Amalgamated Bank now owns 5,488 shares of the company’s stock valued at $180,000 after buying an additional 442 shares in the last quarter. Finally, Jump Financial LLC bought a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at $201,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Truist Financial increased their price objective on shares of PROCEPT BioRobotics from $63.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. Piper Sandler upped their price target on shares of PROCEPT BioRobotics from $67.00 to $75.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Finally, TD Cowen upped their price target on shares of PROCEPT BioRobotics from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, May 6th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $61.20.

Check Out Our Latest Report on PROCEPT BioRobotics

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Featured Stories

Insider Buying and Selling by Quarter for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.